(Q38627084)

4 September 2017

1 reference

title

Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells (English)

1 reference

4 September 2017

1 reference

C M van Haelst-Pisani

series ordinal

1

1 reference

4 September 2017

R J Pisani

series ordinal

2

1 reference

4 September 2017

J S Kovach

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 April 1989

1 reference

4 September 2017

1 reference

4 September 2017

volume

64

1 reference

4 September 2017

issue

4

1 reference

4 September 2017

page(s)

451-465

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Treatment of cancer with lymphokine-activated killer cells and interleukin-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

T lymphocytes: ontogeny, function, and relevance to clinical disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

The detailed distribution of MHC Class II antigens in normal human organs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Lymphokine-activated killer cells. Analysis of progenitors and effectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral bloo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Structure and expression of a cloned cDNA for human interleukin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Human interleukin 2: molecular biology, physiology and clinical possibilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Long term culture of tumour-specific cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Interleukin-2 augments natural killer cell activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Interleukin 2 regulation of mitogen induction of immune interferon (IFN gamma) in spleen cells and thymocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Clinical effects and toxicity of interleukin-2 in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Eosinophilia and fluid retention in systemic administration of interleukin-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Local tumor immunotherapy with in vitro activated autochithonous lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Intraperitoneal administration of interleukin-2 in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumour site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Identification of lymphocyte subsets and natural killer cells in head and neck cancers. An immunohistological study using monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Functional characterization of T lymphocytes propagated from human lung carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

Molecular aspects of human T lymphocyte antigen recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965736-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)65736-X

1 reference

4 September 2017

1 reference